Periostin expression upregulated in leiomyosarcoma Periostin expression upregulated in leiomyosarcoma

Aim: Uterine leiomyosarcomas (LMSs) are rare tumors of the uterus and constitute 1-2% of uterine malignancies. Due to metastases, high recurrence rate and poor prognosis of these tumors, the search for new biomarkers for early diagnosis has increased. In our study, we aimed to show the gene expression and protein level of periostin in leiomyosarcoma as a new biomarker in order to predict prognosis and treatment, together with early diagnosis in leiomyosarcoma. Material and Methods: Between 2010 and 2020, 12 patients diagnosed with "leiomyosarcoma" and 13 patients diagnosed with "myoma" in our tertiary care hospital, after histopathological examination of clinical samples, were included in the study. Tumor cell necrosis, cellular' ty, atypia and mitotic index findings of each patient diagnosed with LMS were examined, and staging was performed using the 2009 International Federation of Gynecology and Obstetrics (FIGO) classification system. The tumor preparations of the cases were taken from the pathology archive and re-evaluated, and the gene expression and protein level of periostin were studied in appropriate blocks using ELISA and PCR methods. Results: According to the FIGO classification, four patients were Stage 1a, six patients were Stage 1b, one patient was Stage 2a, and one patient was Stage 2b. It was determined that the periostin protein was mainly localized in the cytoplasm of leiomyosarcoma cells, and the expression of the periostin gene was increased in cancer tissues compared to myoma tissues, but the difference was not significant (2.1611.79 vs. 4.01t2.84; p-0.062). Although the mean protein level in periostin tissues was higher in leiomyosarcoma cases, the difference was not significant (LMS: 1.6931.52; Myoma: 0.8810.93; p=0.115). Discussion: Our study is the first to examine the relationship between periostin and leiomyosarcoma. The findings of our study show that periostin can be used as a biomarker for leiomyosarcoma.